Cardiac Rehabilitation in Chagas Heart Failure

Learn more about:
Related Clinical Trial
SBRT in Chagas Disease Ventricular Tachycardia Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease New Scheme for Treatment With Benznidazole Outcomes of an Anticoagulation Clinic in an University Hospital Cardiac Rehabilitation in Chagas Heart Failure Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease Exercise Training in Chagas Cardiomyopathy Genetic Architecture of Heart Disease in Rural Brazil Physical Exercise Program in Chronic Chagas Heart Disease Pharmacokinetic Drug-Drug Interaction Study Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure Abbott ESA Chagas Assay Post-Market Study Population Pharmacokinetics Study of Benznidazole in Children With Chagas’Disease Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States Colchicine for Patients With Chagas´ Disease( B1 Stage) Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project) Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas’ Patients Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas’ Patients Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas’ Patients – Dietary Habits Study BENDITA BEnznidazole New Doses Improved Treatment and Associations New Therapies and Biomarkers for Chagas Infection Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy Selenium Treatment and Chagasic Cardiopathy (STCC) Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Congenital Transmission of Lineages I and II of Trypanosoma Cruzi Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Prospective Study of Benznidazole for Chagas’ Disease Children With Chronic Indeterminate Chagas Disease Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Prospective Study of a Pediatric Nifurtimox Formulation for Chagas’ Disease Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease MicroRNAs as Biomarkers in Patients With Chagas Disease Galectin-3 as a Biomarker in Patients With Chagas Disease Syndecan-4 as a Biomarker in Patients With Chagas Disease Population Pharmacokinetics of Benznidazole in Children With Chagas Disease Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease

Brief Title

Cardiac Rehabilitation in Chagas Heart Failure

Official Title

Cardiac Rehabilitation Program in Patients With Chagas Heart Failure: a Pilot Study

Brief Summary

      Due to the lack of information in the literature about the role of cardiac rehabilitation on
      Chagas heart failure, the aim of the present study was to evaluate the effects of a cardiac
      exercise program on functional capacity, cardiac function, respiratory muscle strength, body
      composition, biomarkers and quality of life among Chagas heart failure patients.

Detailed Description

      The present study consisted in a pre/post single-arm intervention study conducted at the
      Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro,
      Brazil. INI is a national reference center for treatment and research in infectious diseases
      and tropical medicine in Brazil, which follows a large cohort of patients with Chagas
      disease, all of them diagnosed by two simultaneously positive serological tests
      (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the
      study were submitted to a physical exercise intervention protocol performed three times per
      week, 60 minutes per session, during an 8-month period. Nutritional and pharmaceutical
      counseling were also monthly provided during the follow-up and consisted on general guidance
      about adequate eating habits for patients with heart failure, mainly sodium and water intake,
      and medication usage, particularly drug dosage and compliance.Patients included in the study
      were followed during an 8-month period in which evaluations of functional capacity (maximal
      progressive cardiopulmonary exercise test), muscle respiratory strength (manovacuometry) and
      body composition (anthropometry and skinfolds) were performed at baseline, after four months
      and at the end of follow-up. Assessments of cardiac function (bidimensional
      echocardiography), biomarkers (lipid profile, glucose and glycated hemoglobin) and quality of
      life (Minnesota Living with Heart Failure questionnaire) were taken at baseline and after
      eight months of follow-up.

Study Phase

Phase 2/Phase 3

Study Type


Primary Outcome

Functional Capacity (VO2 max)

Secondary Outcome

 Muscle respiratory strength (maximal inspiratory pressure and maximal expiratory pressure)


Chagas Disease


Exercise, nutritional and pharmaceutical counseling

Study Arms / Comparison Groups

 Intervention group
Description:  Physical exercise intervention
Nutritional counseling
Pharmaceutical counseling


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 2013

Completion Date

December 2014

Primary Completion Date

January 2014

Eligibility Criteria

        Inclusion Criteria:

          -  Patients at the stages C or D of Chagas cardiomyopathy

          -  Patients receiving standard optimized medical therapy

          -  Patients with good adherence to outpatient treatment within the last three months.

        Exclusion Criteria:

          -  Those who were not able to attend three weekly training sessions,

          -  Those who had neuromuscular limitations, cardiopathies from non-Chagasic etiology (e.g
             ischemic), systemic conditions that limits exercise practice (e.g chronic obstructive
             pulmonary disease)

          -  Practitioners of regular exercise.




18 Years - N/A

Accepts Healthy Volunteers



Andrea S Sousa, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

CAAE 0055.0.009.000-11

Responsible Party

Principal Investigator

Study Sponsor

Evandro Chagas National Institute of Infectious Disease

Study Sponsor

Andrea S Sousa, PhD, Principal Investigator, Evandro Chagas National Institute of Infectious Disease

Verification Date

August 2015